- Home
- MAX vs KROS Comparison
MAX vs KROS Comparison
Compare MAX & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- KROS
- Stock Information
- Founded
- MAX 2014
- KROS 2015
- Country
- MAX United States
- KROS United States
- Employees
- MAX N/A
- KROS N/A
- Industry
- MAX Industrial Machinery/Components
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- MAX Industrials
- KROS Health Care
- Exchange
- MAX Nasdaq
- KROS Nasdaq
- Market Cap
- MAX 613.7M
- KROS 589.8M
- IPO Year
- MAX 2020
- KROS 2020
- Fundamental
- Price
- MAX $11.14
- KROS $10.86
- Analyst Decision
- MAX Buy
- KROS Buy
- Analyst Count
- MAX 8
- KROS 11
- Target Price
- MAX $22.00
- KROS $45.33
- AVG Volume (30 Days)
- MAX 460.9K
- KROS 2.0M
- Earning Date
- MAX 02-18-2025
- KROS 02-26-2025
- Dividend Yield
- MAX N/A
- KROS N/A
- EPS Growth
- MAX N/A
- KROS N/A
- EPS
- MAX 0.19
- KROS N/A
- Revenue
- MAX $681,230,000.00
- KROS $651,000.00
- Revenue This Year
- MAX $124.41
- KROS $303.39
- Revenue Next Year
- MAX $31.11
- KROS N/A
- P/E Ratio
- MAX $59.01
- KROS N/A
- Revenue Growth
- MAX 72.47
- KROS 8037.50
- 52 Week Low
- MAX $10.21
- KROS $9.78
- 52 Week High
- MAX $25.78
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- MAX 45.21
- KROS 20.25
- Support Level
- MAX $10.28
- KROS $9.78
- Resistance Level
- MAX $11.51
- KROS $16.49
- Average True Range (ATR)
- MAX 0.47
- KROS 0.92
- MACD
- MAX 0.08
- KROS 0.97
- Stochastic Oscillator
- MAX 53.26
- KROS 14.52
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.